Patient Access Analytics solution combines coverage and claims data to provide a unique view of payer and prescriber behavior—offering instant answers using real-world data—to help patients access lifesaving treatments faster
Following the acquisition of healthcare analytics company Panalgo in September 2021, Managed Markets Insight & Technology (MMIT) has announced the launch of Patient Access Analytics, a solution that provides pharma commercial teams with the ability to quickly analyze and visualize multiple longitudinal, real-world patient data sets to instantly obtain answers to questions regarding access barriers and prescribing patterns.
“Smoothing a patient’s access to lifesaving treatments is our true north, and we’re proud to offer this industry-leading solution that delivers instant answers—not just insights—so that pharma manufacturers can make strategic, data-driven decisions in real time,” said MMIT CEO Mike Gallup.
Recommended AI News: Metamall Prepares For listing, Launches First of Its Kind Decentralized Metaverse Mall
With drug innovation today focused on precise treatments for highly targeted patient populations, pharma manufacturers are increasing their investment in real-world data to understand patient populations, prescriber behavior, provider-payer mix, and the implications for the patient.
These large data sets require significant mapping, normalization and analysis, and often leave pharma manufacturers seeking insights through many expensive, ineffective avenues. MMIT’s Patient Access Analytics solution leverages the deep flexibility and transparent architecture of Panalgo’s data-agnostic Instant Health Data (IHD) platform so that claims data can be visualized in an integrated fashion alongside MMIT’s market-leading policy and restriction coverage data.
“As our clients know, there’s no shortage of real-world data. With Patient Access Analytics, clients can get the answers they need using their existing data instead of purchasing yet another data set,” said Gallup. “It’s an extremely valuable tool.”
Jordan Menzin, CEO of Panalgo, added: “We are excited by this combined offering because it allows our clients to truly understand the magnitude of how coverage decisions influence and change physician prescribing behavior and, ultimately, how it affects patient care. This level of insight informs what’s happening in the real world, in real time, and allows pharma companies to pivot their commercial strategies to help patients get the care that they need.”
Recommended AI News: Bitengen Changes Global Fintech Market with Crypto and NFT Exchange
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.